Evogene Ltd
EVGN
View Detailed Chart
1.180USD
+0.030+2.61%
Close 11/10, 16:00（ET）Quotes delayed by 15 min
10.28MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.61%
5 Days
-6.35%
1 Month
-11.94%
6 Months
+4.19%
Year to Date
-36.90%
1 Year
-32.95%
View Detailed Chart
TradingKey Stock Score of Evogene Ltd
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Evogene Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
2.500
Target Price
+117.39%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Evogene Ltd Highlights
StrengthsRisks
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 408.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 8.51M.
Undervalued
The company’s latest PE is -0.55, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 144.62K shares, decreasing 83.28% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.82.
Evogene Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Evogene Ltd Info
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Ticker SymbolEVGN
CompanyEvogene Ltd
CEODr. Arnon Heyman
Websitehttps://evogene.com/
Related Instruments
+4.61%
+0.97%
-0.21%
+3.45%
+0.68%
+0.53%
+1.10%
+0.59%
-0.60%
-0.12%
+2.01%
+2.88%
+0.86%
+1.21%
+1.57%
+1.32%
0.00%
-0.45%
-0.27%
+1.82%
